Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Deucravacitinib Solid Tablet Formulations
NCT04949269Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deucravacitinib in plaque psoriasis (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Plasma Concentration up to 7 days, Area Under the Concentration-time Curve up to 7 days and 1 more. Started Jul 2021; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04949269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04949269.